ATE328896T1 - Faktor viii vom schwein und hybriden - Google Patents

Faktor viii vom schwein und hybriden

Info

Publication number
ATE328896T1
ATE328896T1 AT97933180T AT97933180T ATE328896T1 AT E328896 T1 ATE328896 T1 AT E328896T1 AT 97933180 T AT97933180 T AT 97933180T AT 97933180 T AT97933180 T AT 97933180T AT E328896 T1 ATE328896 T1 AT E328896T1
Authority
AT
Austria
Prior art keywords
factor viii
pork
hybrids
modified factor
viii proteins
Prior art date
Application number
AT97933180T
Other languages
English (en)
Inventor
John S Lollar
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE328896T1 publication Critical patent/ATE328896T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97933180T 1996-06-26 1997-06-26 Faktor viii vom schwein und hybriden ATE328896T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/670,707 US5859204A (en) 1992-04-07 1996-06-26 Modified factor VIII

Publications (1)

Publication Number Publication Date
ATE328896T1 true ATE328896T1 (de) 2006-06-15

Family

ID=24691532

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97933180T ATE328896T1 (de) 1996-06-26 1997-06-26 Faktor viii vom schwein und hybriden

Country Status (11)

Country Link
US (1) US5859204A (de)
EP (2) EP1561757A1 (de)
JP (2) JP3611860B2 (de)
AT (1) ATE328896T1 (de)
AU (1) AU717686B2 (de)
CA (1) CA2258502C (de)
DE (1) DE69736068T2 (de)
DK (1) DK0939767T3 (de)
ES (1) ES2267146T3 (de)
PT (1) PT939767E (de)
WO (1) WO1997049725A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1129186B2 (de) * 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
EP1183354A2 (de) 1999-05-24 2002-03-06 The American National Red Cross Verfahren, die dem abbau von faktor-viii entgegenwirken, und dazugehörigen zusammensetzungen
MXPA03002256A (es) * 2000-09-19 2003-09-10 Univ Emory Factor viii modificado.
EP1351986A2 (de) * 2001-01-12 2003-10-15 The American National Red Cross Verfahren und zusammensetzungen zur verminderung von heparansulfatproteoglykan-vermittelter entfernung von faktor viii
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
CA2461443C (en) * 2001-10-05 2011-07-12 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
MXPA04005079A (es) * 2001-11-30 2004-08-19 Univ Emory Variantes del dominio c2 del factor viii.
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
EP1682106A4 (de) * 2003-10-30 2008-06-11 Univ Emory Modifiziertes fviii mit verringerter immunogenität durch mutagenese von a2- und c2-epitopen
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US7855274B2 (en) * 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
JP2007536230A (ja) * 2004-05-03 2007-12-13 エモリー ユニバーシティ ブタＢドメイン欠損ｆＶＩＩＩの投与方法
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
WO2006103298A2 (en) * 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
CN101848731A (zh) * 2007-05-07 2010-09-29 肽免疫公司 用作抗体配体的表位定向扩增的方法
EP2209908B1 (de) 2007-11-01 2014-09-03 University Of Rochester Rekombinanter faktor viii mit erhöhter stabilität
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
WO2011088391A2 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
JP5826772B2 (ja) * 2010-02-16 2015-12-02 ノヴォ ノルディスク アー／エス コンジュゲートタンパク質
EP2536754A1 (de) * 2010-02-16 2012-12-26 Novo Nordisk A/S Faktor-viii-fusionsproteine
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
CA2816575C (en) 2010-11-05 2019-06-11 Baxter Healthcare S.A. A new variant of antihemophilic factor viii having increased specific activity
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
DK2729161T3 (en) 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
BR112014017111A8 (pt) 2012-01-12 2018-05-15 Biogen Idec Inc métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
CN111499761A (zh) 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
EP2666782A1 (de) * 2012-05-22 2013-11-27 Imnate Sarl Gerinnungsfaktor VII mit reduzierter Immunogenität
AU2013290173B2 (en) 2012-07-11 2018-02-15 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3970738A1 (de) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blutfaktorüberwachungstest und verwendungen davon
EP2908847B1 (de) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Verfahren zur verwendung einer festgelegten dosis eines blutgerinnungsfaktors
EP2914293A4 (de) 2012-10-30 2016-04-20 Biogen Ma Inc Verfahren zur verwendung von fviii-polypeptid
WO2014089541A2 (en) 2012-12-07 2014-06-12 Haplomics, Inc. Factor viii mutation repair and tolerance induction
EP3666283B1 (de) 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Faktor-viii-polypeptidformulierungen
US20160102133A1 (en) 2013-06-24 2016-04-14 Weidong Xiao Mutant factor viii compositions and methods
HK1223302A1 (zh) 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 具有xten的凝血酶可裂解连接子和其用途
EP3043813B1 (de) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
PH12016501323B1 (en) 2014-01-10 2022-04-29 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
EP3114138B1 (de) 2014-03-05 2021-11-17 Pfizer Inc. Verbesserte muteine von gerinnungsfaktor viii
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
EP4314041A1 (de) 2021-03-30 2024-02-07 Aavnergene Inc. Modifizierter plasmagerinnungsfaktor viii und verfahren zu dessen verwendung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5149637A (en) * 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US5171844A (en) * 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) * 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6291896A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
AU6455896A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties

Also Published As

Publication number Publication date
AU717686B2 (en) 2000-03-30
EP1561757A1 (de) 2005-08-10
CA2258502C (en) 2003-04-29
JP3611860B2 (ja) 2005-01-19
JP2004141173A (ja) 2004-05-20
JP2000513934A (ja) 2000-10-24
US5859204A (en) 1999-01-12
ES2267146T3 (es) 2007-03-01
EP0939767B1 (de) 2006-06-07
WO1997049725A9 (en) 2005-11-17
DE69736068T2 (de) 2006-12-14
WO1997049725A1 (en) 1997-12-31
JP3683897B2 (ja) 2005-08-17
DE69736068D1 (de) 2006-07-20
HK1022480A1 (en) 2000-08-11
CA2258502A1 (en) 1997-12-31
EP0939767A1 (de) 1999-09-08
EP0939767A4 (de) 2001-04-04
PT939767E (pt) 2006-10-31
DK0939767T3 (da) 2006-10-09
AU3643397A (en) 1998-01-14

Similar Documents

Publication Publication Date Title
ATE328896T1 (de) Faktor viii vom schwein und hybriden
EP0918787A4 (de) Zusammensetzungen und methoden zur gegenstrang-hemmung der proteinübersetzung
DE69737580D1 (de) Bindemittel enthaltend Transglutaminase und Kollagen, und Verfahren zur Herstellung von gebundenen Nahrungsmittel
DE69941267D1 (de) Proteingerüste für antikörper-nachahmer und andere bindende proteine
PT907735E (pt) Moduladores da regeneracao de tecidos
DE69433934D1 (de) Verfahren und Zusammensetzungen zur erhöhten Proteinproduktion von rekombinanter DNA
DE69707849D1 (de) Verfahren zur reinigung von 1,4-butandiol
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
ATE247719T1 (de) Mittel zur herstellung von leder
DE69715234D1 (de) Verfahren zur reinigung von 1,1-difluorethan
ATE91262T1 (de) Geblasene, einstueckige flasche und verfahren zur herstellung derselben.
EP0749496A4 (de) Menschliche dna fehlpaarungsreperatur proteine
ATE219767T1 (de) Verfahren zur herstellung von 2,4-dihydroxy- pyridin und 2,4-dihydroxy-3-nitropyridin
DE69513426D1 (de) Markier-Zusammensetzung, daraus hergestelltes Formteil und Markierungsverfahren
DE69515697D1 (de) Blockcopolymere und verfahren zur herstellung
DE69734464D1 (de) Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
ATE252112T1 (de) Prozess zur herstellung von aza zyclohexapeptide
DE59810658D1 (de) Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung desselben
DE69532874D1 (de) RPDL Protein und kodierende DNS
DE69717115D1 (de) Verfahren zur herstellung von 1,1,1,3,3-pentafluorpropan
GB9421093D0 (en) Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
ATE284390T1 (de) Verfahren und zwischenprodukte zur herstellung von 2,3-pyridindicarboxylatderivaten
DE69711039D1 (de) Verfahren zur herstellung von 1,3-alkandiolen
DE59510636D1 (de) Verfahren zur herstellung von 8-alpha,12-oxido-13,14,15,16-tetranorlabdan

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0939767

Country of ref document: EP